Home › NDC Lookup › Ingredients › Metoprolol Succinate › 75834-0291-99
⚪image loading
(from DailyMed)

Metoprolol Succinate 50 mg Tablet, Extended Release, 113,000-count — NDC 75834-291-99 (Billing 75834-0291-99)

by Nivagen Pharmaceuticals, Inc · 113000 TABLET, EXTENDED RELEASE in 1 DRUM

This is a package of 113,000 tablets of Metoprolol Succinate 50 mg Tablet, Extended Release from Nivagen Pharmaceuticals, Inc, marketed since Nov 2020 and currently FDA-listed.

NDC 75834-0291-99
🏷️ FDA NDC (as labeled) 75834-291-99 billing pads the product segment with a zero
This package
Contains113,000-count Pack sizes4 compare ↓
Product page 75834-0291-00 Also comes in: 100 tablets 75834-291-01 500 tablets 75834-291-05 1000 tablets 75834-291-00
On market Non-controlled ⇄ Compare with another NDC
🗂️ FDA directory synced Oct 1, 2026 · this listing last changed Sep 3, 2026 · sources: openFDA · FDA label (DailyMed) · FDA Orange & Purple Book · First Databank · CMS NADAC, ASP, Medicare & Medicaid · RxNorm
📋 All sources & update times →

This page is curated, coded, and maintained by

Compiled from public FDA, CMS, DailyMed, NADAC, and related drug data sources. Editorial policy

⚠️
Other active recalls for Metoprolol Succinate (different manufacturers) — 5 · tap to view
These affect other manufacturers’ products for the same ingredient — not necessarily the exact NDC on this page.
Class II · Jan 29, 2026 — Failed Dissolution Specifications (Teva Pharmaceuticals USA, Inc) · FDA recall D-0355-2026
Class II · Jan 29, 2026 — Failed Dissolution Specifications (Teva Pharmaceuticals USA, Inc) · FDA recall D-0354-2026
Class II · Jan 29, 2026 — Failed Dissolution Specifications (Teva Pharmaceuticals USA, Inc) · FDA recall D-0357-2026
Class II · Jan 29, 2026 — Failed Dissolution Specifications (Teva Pharmaceuticals USA, Inc) · FDA recall D-0356-2026
Class II · Jun 24, 2025 — Failed Dissolution Specifications: Product failed to meet dissolution acceptance criteria in the stability studies at the 6th month (25¿C/60% RH) long-term. (Granules Pharmaceuticals Inc.) · FDA recall D-0510-2025
Each entry is an official FDA enforcement report — look up any recall number in the FDA recall database ↗

Identity & classification

Regulatory identifiers FDA, NLM and CMS codes for this package

FDA NDC (as labeled) 75834-291-99
Product NDC 75834-291
11-digit billing NDC 75834029199
SPL Set ID d3ce48ab-ebc6-f778-e053-2995a90a6e9f
DEA schedule Non-controlled
Marketing category DRUG FOR FURTHER PROCESSING
Marketing status On market
FDA listing status Listed (active directory)
Marketing start 2020-11-20
Dosage form TABLET, EXTENDED RELEASE
Substance METOPROLOL SUCCINATE

Drug-database identifiers Medi-Span GPI and First Databank GCN / HICL / AHFS classification

GPI-14 33200030057520
GPI class Metoprolol Succinate ER
GCN Seq No 016599
GCN 20741
HICL code 006323
Ingredient (HICL) Metoprolol Succinate
HIC1 code J
Therapeutic class — broad (HIC1) Autonomic Nervous System
HIC2 code J7
Therapeutic class — intermediate (HIC2) Antiadrenergics
HIC3 code J7C
Therapeutic class — specific (HIC3) Beta-Adrenergic Blocking Agents
AHFS code 12:16.08.08
AHFS class Selective Beta-Adrenergic Blocking Agent
FDB label name METOPROLOL SUCC ER 50 MG TAB
FDB brand name Metoprolol Succinate
Legend status F — Federal legend — prescription drug or device
Quick answers
  • GSN (GCN sequence number): 016599
  • GCN: 20741
  • GPI-14 (Medi-Span): 33200030057520
  • HICL (First Databank): 006323
  • AHFS class code: 12:16.08.08
Why two NDCs? The FDA registers this code as 75834-291-99 — a 5-3-2 layout, and that's what's printed on the package and shown on DailyMed. For insurance claims, every NDC is standardized to a uniform 11-digit 5-4-2 format by adding a zero to the product segment → 75834-0291-99. Same drug, same package — only the format differs.
Where does this data come from?
Identifiers from the FDA openFDA NDC Directory and Structured Product Labeling; RxCUI from RxNorm (NLM); GPI from Medi-Span; GCN / HIC / AHFS / legend from First Databank.

Clinical

Label name METOPROLOL SUCC ER 50 MG TAB Ingredient Metoprolol Succinate
📗 Our plain-language guide HelloPharmacist
  • It depends on which form you have. Metoprolol tartrate and Lopressor tablets treat high blood pressure and angina, and lower the risk of death after a heart attack. Metoprolol succ...
  • Take it exactly as prescribed. Tartrate tablets go with or right after a meal. Extended-release succinate tablets are taken once daily and should not be crushed or chewed. Ask your...
  • Please don't stop suddenly. Stopping abruptly can make angina worse and has led to heart attacks. Even if you only take it for blood pressure, your doctor will lower the dose gradu...
  • Tiredness, dizziness, a slow heartbeat, low blood pressure, diarrhea, itching or rash are the more common ones. Most were mild and temporary. Call your doctor if you faint, your he...
📖 Read our full Metoprolol guide →

Supplement & herbal interactions

🌿 Drug–supplement interaction checker →
1
Nutrient depletion considerations

Metoprolol may be associated with lower levels of 1 nutrient — worth a chat with your pharmacist, not a cause for alarm.

🧪 Full Metoprolol nutrient depletion report →
An association is not a deficiency. Educational only — don't start or stop anything without professional guidance.
Where does this data come from?
Plain-language summary from MedlinePlus (U.S. National Library of Medicine); supplement & herbal interactions and nutrient depletion data from the Natural Medicines database; our full guide is HelloPharmacist editorial content.

Pricing

A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.

Price systemPer eachPer package
Retail pharmacies payNADAC · weekly Not in the retail survey — common for institutional, discontinued, or low-volume packs.
Medicaid paysCMS SDUD · 12 mo No recent Medicaid claims on file for this NDC — rare and low-volume NDCs are suppressed in the public data.
Medicare drug plans payPart D · quarterly No Part D plan price is available for this NDC in our data.
ℹ️
No price is published for this exact package yet. CMS surveys NADAC per package size, so a different pack of the same drug often has one.
Try another pack size: 100 tablets 500 tablets 1000 tablets
Where does this data come from?
NADAC (National Average Drug Acquisition Cost) is the CMS weekly pharmacy-acquisition-cost survey — what pharmacies pay. ASP (Average Sales Price) is the CMS Medicare Part B drug-payment file, published quarterly. Medicaid pays is computed by us from CMS State Drug Utilization Data (total reimbursed ÷ units, trailing 12 months) — gross of rebates and inclusive of dispensing fees, so it reflects what Medicaid paid, not an acquisition cost. Medicare drug plans pay is the median negotiated point-of-sale unit cost across plans listing this NDC in the CMS quarterly Prescription Drug Plan pricing files, before rebates. The VA pays is the federal contract price (FSS, and the statutory Big 4 ceiling where listed) from the VA National Acquisition Center pharmaceutical price file. All are free public government data; each measures a different payer, so the figures are not directly comparable.

Packaging — all sizes for this product

Package NDCDescription Per unit Per pack Marketing startMarketing endStatus
75834-0291-00 75834-291-00 Main listing 1000 TABLET, EXTENDED RELEASE in 1 BOTTLE $0.0587 / ea $58.74 2022-02-23 — Discontinued by firm
75834-0291-01 75834-291-01 100 TABLET, EXTENDED RELEASE in 1 BOTTLE $0.0714 / ea $7.14 2022-02-23 — Discontinued by firm
75834-0291-05 75834-291-05 500 TABLET, EXTENDED RELEASE in 1 BOTTLE — — 2022-02-23 — Discontinued by firm
75834-0291-99 You're viewing this 113000 TABLET, EXTENDED RELEASE in 1 DRUM — — — — Active

You're viewing the largest of 4 pack sizes for this product.

This pack shows little to no recent Medicaid volume — the 1000 tablets pack carries most fills. See all packs ↓

Pack size FAQ

What quantity is in this package?
This is a 113,000-count package — 113000 tablet, extended release in 1 drum.
How does this package differ from NDC 75834-0291-01?
Both are Metoprolol Succinate 50 mg Tablet, Extended Release — the drug itself is identical. This page's package is the 113,000-count one, while NDC 75834-0291-01 is the 100 tablets package.
What NDC number is used to bill for this package of Metoprolol Succinate 50 mg Tablet, Extended Release?
Use the 11-digit billing form listed in the identifiers section of this page. Pharmacy and medical claims use the 11-digit form; the FDA label may print a shorter form of the same code.

Prices are the latest CMS NADAC pharmacy acquisition cost per NDC; per-pack figures are per-unit × pack quantity, shown only when the pack is denominated in the same measure NADAC prices.

Therapeutic equivalents

ProductLabelerPackNADAC/unitTEStatusPrice vs. this
Metoprolol succinate 50 mg 00904-6323-61 Major 1 tablet $0.052 AB Availability likely —
Metoprolol Succinate 50 mg 27808-0303-01 Cranbury 100 tablets $0.052 AB Availability likely —
Metoprolol Succinate 50 mg 31722-0590-01 Camber 100 tablets $0.052 AB Availability likely —
Metoprolol succinate 50 mg 42806-0725-01 Epic 100 tablets $0.052 AB Availability likely —
metoprolol succinate 50 mg 45963-0676-11 Actavis 100 tablets $0.052 AB Availability likely —
Metoprolol succinate 50 mg 50268-0541-15 AvPAK 1 tablet $0.052 AB Availability likely —
Metoprolol Succinate 50 mg 50742-0616-01 Ingenus 100 tablets $0.052 AB Availability likely —
Metoprolol succinate 50 mg 55111-0467-01 Dr. 100 tablets $0.052 AB Availability likely —
Metoprolol Succinate 50 mg 60687-0402-01 American 1 tablet $0.052 AB Availability likely —
Metoprolol Succinate 50 mg 67877-0591-01 Ascend 100 tablets $0.052 AB Availability likely —
Metoprolol Succinate 50 mg 68001-0469-00 BluePoint 100 tablets $0.052 AB Availability likely —
Metoprolol Succinate 50 mg 68001-0501-00 BluePoint 100 tablets $0.052 AB Availability likely —
Metoprolol Succinate 50 mg 68001-0685-00 BluePoint 100 tablets $0.052 AB Availability likely —
metoprolol succinate 50 mg 68382-0565-01 Zydus 100 tablets $0.052 AB Availability likely —
Metoprolol Succinate 50 mg 70010-0781-01 Granules 100 tablets $0.052 AB Availability likely —
Metoprolol Succinate 50 mg 72516-0031-01 Oryza 100 tablets $0.052 AB Availability likely —
Metoprolol succinate 50 mg 72603-0143-01 Northstar 100 tablets $0.052 AB Availability likely —
Metoprolol succinate 50 mg 75907-0347-01 Dr. 100 tablets $0.052 AB Availability likely —
Metoprolol succinate 50 mg 82009-0114-05 Quallent 500 tablets $0.052 AB Availability likely —
Metoprolol succinate 50 mg 70436-0183-01 Slate 100 tablets $0.054 AB Availability likely —
Toprol Xl 50 mg 70842-0111-02 Melinta 100 tablets $1.385 AB Availability likely —
Metoprolol succinate 50 mg 00615-7824-05 NCS 15 tablets — AB FDA listed —
Metoprolol Succinate 50 mg 50090-5722-00 A-S 30 tablets — AB FDA listed —
Metoprolol Succinate 50 mg 50090-5723-00 A-S 90 tablets — AB FDA listed —
Metoprolol Succinate 50 mg 50090-6448-00 A-S 30 tablets — AB FDA listed —
Metoprolol Succinate 50 mg 50090-6662-00 A-S 30 tablets — AB FDA listed —
Metoprolol Succinate 50 mg 50090-6663-00 A-S 90 tablets — AB FDA listed —
Metoprolol succinate 50 mg 50090-7238-00 A-S 30 tablets — AB FDA listed —
Metoprolol succinate 50 mg 50090-7239-00 A-S 90 tablets — AB FDA listed —
Metoprolol Succinate 50 mg 51407-0404-01 Golden 100 tablets — AB FDA listed —
Metoprolol Succinate 50 mg 51655-0203-52 Northwind 30 tablets — AB FDA listed —
metoprolol succinate 50 mg 51655-0519-26 Northwind 90 tablets — AB FDA listed —
Metoprolol succinate 50 mg 51655-0919-26 Northwind 90 tablets — AB FDA listed —
Metoprolol succinate 50 mg 53401-0009-30 Aphena 30 tablets — AB FDA listed —
Metoprolol succinate 50 mg 55154-6886-00 Cardinal 1 tablet — AB FDA listed —
metoprolol succinate 50 mg 60760-0634-90 St 90 tablets — AB FDA listed —
Metoprolol succinate 50 mg 60760-0993-90 ST. 90 tablets — AB FDA listed —
Metoprolol Succinate 50 mg 62207-0133-49 Granules 1000 tablets — — FDA listed —
Metoprolol Succinate 50 mg 63629-8864-01 Bryant 100 tablets — AB FDA listed —
Metoprolol Succinate 50 mg 63629-9169-01 Bryant 1000 tablets — AB FDA listed —
Metoprolol Succinate 50 mg 63629-9170-01 Bryant 500 tablets — AB FDA listed —
Metoprolol succinate 50 mg 67046-1650-03 Coupler 30 tablets — AB FDA listed —
metoprolol succinate 50 mg 67296-1902-03 Redpharm 30 tablets — AB FDA listed —
metoprolol succinate 50 mg 68071-2522-01 NuCare 100 tablets — AB FDA listed —
Metoprolol succinate 50 mg 68071-3828-01 NuCare 100 tablets — AB FDA listed —
Metoprolol Succinate 50 mg 68071-3943-01 NuCare 100 tablets — AB FDA listed —
Metoprolol Succinate 50 mg 68071-3965-09 NuCare 90 tablets — AB FDA listed —
metoprolol succinate 50 mg 68788-7997-01 Preferred 100 tablets — AB Discontinued —
Metoprolol Succinate 50 mg 68788-8312-01 Preferred 100 tablets — AB FDA listed —
Metoprolol Succinate 50 mg 68788-8869-03 Preferred 30 tablets — AB FDA listed —
Metoprolol Succinate 50 mg 69097-0407-02 Cipla 30 tablets — AB FDA listed —
metoprolol succinate 50 mg 70518-3164-00 REMEDYREPACK 30 tablets — AB FDA listed —
Metoprolol Succinate 50 mg 70518-3680-00 REMEDYREPACK 90 tablets — AB Discontinued —
metoprolol succinate 50 mg 70771-1339-00 Zydus 1000 tablets — AB FDA listed —
Metoprolol Succinate 50 mg 71205-0162-30 Proficient 30 tablets — AB FDA listed —
Metoprolol Succinate 50 mg 71205-0179-30 Proficient 30 tablets — AB FDA listed —
Metoprolol Succinate 50 mg 71205-0724-30 Proficient 30 tablets — AB FDA listed —
metoprolol succinate 50 mg 71205-0800-30 Proficient 30 tablets — AB FDA listed —
Metoprolol succinate 50 mg 71335-0149-01 Bryant 30 tablets — AB FDA listed —
metoprolol succinate 50 mg 71335-1878-01 Bryant 30 tablets — AB FDA listed —
Metoprolol Succinate 50 mg 71335-2835-01 Bryant 100 tablets — AB FDA listed —
Metoprolol Succinate 50 mg 71335-3052-01 Bryant 30 tablets — AB FDA listed —
Metoprolol Succinate 50 mg 71335-9749-01 Bryant 30 tablets — AB FDA listed —
Metoprolol Succinate 50 mg 71335-9753-01 Bryant 30 tablets — AB FDA listed —
Metoprolol Succinate 50 mg 71610-0642-45 Aphena 45 tablets — AB FDA listed —
Metoprolol succinate 50 mg 71765-0006-01 Zhejiang 100 tablets — AB FDA listed —
Metoprolol Succinate 50 mg 72162-1857-00 Bryant 1000 tablets — AB FDA listed —
Metoprolol Succinate ER 50 mg 72189-0547-90 Direct_Rx 90 tablets — AB FDA listed —
Metoprolol succinate 50 mg 72516-0026-01 Oryza 100 tablets — AB FDA listed —
Metoprolol Succinate 50 mg 72789-0010-30 PD-Rx 30 tablets — AB FDA listed —
Metoprolol succinate 50 mg 72789-0284-30 PD-Rx 30 tablets — AB FDA listed —
Metoprolol Succinate 50 mg 72789-0497-90 PD-Rx 90 tablets — AB FDA listed —
Metoprolol Succinate 50 mgthis 75834-0291-99 Nivagen 113000 tablets — — FDA listed —
Metoprolol Succinate 50 mg 82804-0014-30 Proficient 30 tablets — AB FDA listed —
metoprolol succinate 50 mg 82804-0198-90 Proficient 90 tablets — AB FDA listed —
Metoprolol Succinate 50 mg 82868-0084-30 Northwind 30 tablets — AB FDA listed —
Metoprolol succinate 50 mg 17228-0109-01 AstraZeneca 36000 tablets — — FDA listed —
Metoprolol Succinate 50 mg 60050-0002-99 Pharmadax 113000 tablets — — FDA listed —
Metoprolol succinate 50 mg 67046-1685-03 Coupler 30 tablets — AB FDA listed —
Metoprolol Succinate 50 mg 82804-0301-90 Proficient 90 tablets — AB FDA listed —
Metoprolol succinate 50 mg 67296-2301-03 Redpharm 30 tablets — AB FDA listed —
About this product: other versions of the same ingredient, strength and form are listed above, least expensive first, with FDA equivalence ratings where available.
Where does this data come from?
Equivalents are other NDCs of the same ingredient, form and route from the openFDA NDC Directory, ranked least-expensive-first by NADAC. Therapeutic-equivalence (AB) ratings come from the FDA Orange Book; biologics use the FDA Purple Book for biosimilar & interchangeable status.

Availability & generic status

🏛️
2020
On the market since
Nov 2020
📍
2026
Currently FDA-listed
6 years listed
🔓
·
Generic versions listed
see equivalents
✅Generic appears available

FDA-approved generic versions are listed, and recent pricing/market data suggests they may be available — see Therapeutic equivalents.

Where does this data come from?
Patents and exclusivity from the FDA Orange Book (small-molecule drugs), refreshed from public FDA data. Generic launch timing is an estimate, not a guarantee.

Inactive Ingredients / Excipients

Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.

Loading inactive ingredients from the official FDA label in the background. No external source is being called by this page request.
Where does this data come from?
Source: official FDA Structured Product Labeling (SPL) via DailyMed and the openFDA label index. Structured IACT rows and label-wide narrative are kept separate; availability and product-level specificity depend on the submitted label.

Inactive ingredient FAQ

Are inactive ingredients the same for every manufacturer?
No. Inactive ingredients can differ by manufacturer, dosage form, strength, and package / product version.
Why might an inactive ingredient be missing?
Some SPLs do not provide a complete structured inactive-ingredient list, and older or unusual labels may only include the information in narrative text.
Can inactive ingredients matter?
Yes. They can matter for allergies, intolerances, dyes, gluten / lactose concerns, preservatives, and formulation differences — but confirm with a pharmacist or the manufacturer when it’s clinically important.

Manufacturer & labeler

LabelerNivagen Pharmaceuticals, Inc
Labeler code75834
First marketedNov 2020
Product typeDrug For Further Processing
Portfolio4 products on file
The labeler markets the product; the application holder owns the FDA approval. They’re often the same company but can differ (e.g. a repackager or an authorized generic). A mailing address / phone appears here when the manufacturer includes it in the product’s FDA label (not all do).
Where does this data come from?
Labeler, application holder and registered establishment from the FDA openFDA NDC Directory and Drugs@FDA; address/contact from the product’s FDA label.

Full FDA label FDA SPL

The complete FDA label for this product, verbatim, section by section. Jump with a chip, search within the label, or expand everything.
📄 FDA label
📄 FDA label 19 words ▾

No FDA label is on file for this product yet. Labels load from openFDA / DailyMed and refresh weekly.

Source: FDA Structured Product Labeling, mirrored from DailyMed / openFDA. Prefer the government’s original formatting? View this label on DailyMed ↗

Medicaid utilization by pack size

Medicaid (SDUD) totals over the four most recent reported quarters for every package size of this drug — handy when a specific package (e.g. a starter/titration pack) carries little or no Medicaid volume on its own.
1000 tablets75834-0291-00 716 Rx · $6,991
100 tablets75834-0291-01 No Medicaid data
500 tablets75834-0291-05 No Medicaid data
113000 tablets this page75834-0291-99 No Medicaid data
Drug total (last 4 qtrs): 716 Rx · 28,609 units · $6,991 gross reimbursed
Tap a pack size to open its page. Source: CMS State Drug Utilization Data, last 4 quarters.

Medicare Part D spend CMS · PART D · 2026 (Q1)

Medicare Part D (outpatient prescription) spending for Metoprolol Succinate (matched by generic name) — the program that covers self-administered drugs. 23 manufacturers.
⚠️ Drug-level data: CMS publishes Part D spending by drug, not by NDC — these figures combine every manufacturer, strength and package size sold under the name Metoprolol Succinate. CMS lists 3 products for this generic; we show the highest-spend one. That’s a different level of aggregation than the Medicaid card above, which is specific to this exact 11-digit NDC (pack size included), so the two aren’t directly comparable.
Period
Total Part D spend
$119.69M
Claims incl. refills
8.6M
Beneficiaries
6.5M
Spend / beneficiary
$18.38
Spend / claim
$13.98
Trend by period
💵 About the dollar figures: spending is what Part D plans paid before confidential manufacturer rebates, so the program’s real net cost is lower. A blank patient count means fewer than 11 people — CMS hides counts that small to protect privacy. Source: CMS Medicare Quarterly Part D Spending by Drug (data.cms.gov), updated quarterly.

About this NDC listing & data coverage

Listed for further processing / repackaging

What "drug for further processing" means

FDA lists this package under the "drug for further processing" marketing category: Nivagen Pharmaceuticals, Inc supplies it to other companies for further processing or repackaging (blister cards that are later repackaged or co-packaged are a common example). The units themselves are a finished dosage form — which is why pricing or Medicaid data can still appear — but this exact package code may not be the presentation a retail pharmacy dispenses.

What data is (and isn’t) available for this NDC — tap to expand
NDC identity (package / product / labeler codes) ✓ Available
Labeler ✓ Available
Product & package description ✓ Available
Marketing category & status ✓ Available
Active ingredient / dosage form / route ✓ Available
FDA label (SPL via DailyMed) ✓ Available
Package photos — Not published for this NDC No photo available yet for this listing.
Inactive ingredients (structured) — Not published for this NDC The labeler did not submit a structured excipient list, or no SPL is available.
NADAC pharmacy acquisition price (CMS) — Not published for this NDC CMS publishes NADAC only for NDCs reported in its retail-pharmacy survey.
Orange Book / therapeutic-equivalence data — Not published for this NDC Applies only to products approved under an NDA/ANDA; many listings are out of scope.
HCPCS J-code billing crosswalk — Not published for this NDC Most self-administered / retail products have no J-code — that is normal.
Medicaid utilization (CMS SDUD) — Not published for this NDC CMS reports utilization only for NDCs with Medicaid claims above its privacy threshold.
“Not published” reflects what the public FDA / CMS / NLM sources provide for this exact package code — it is a property of the data feeds, not a judgment about the product.

Questions about this listing

Is this NDC FDA-approved?
An NDC listing does not by itself establish FDA approval — the NDC Directory records that a product is listed with FDA, not that it was reviewed and approved. This listing's marketing category is "Drug For Further Processing". Products approved under an application carry an NDA, ANDA, or BLA number.
Why is there no price listed?
The pricing shown on our NDC pages comes from CMS NADAC, a voluntary survey of retail community pharmacy invoices. CMS does not publish a NADAC for every NDC — packages outside the retail survey (institutional and hospital products, bulk packages, discontinued items, and many OTC items) may never receive one. A missing price reflects the survey's scope, not this product's actual cost, and does not mean the product is free or unavailable.
Is the NDC printed on the package the same as the 11-digit billing NDC?
Yes, they identify this exact package in different formats. The form printed on the packaging and shown on DailyMed is the one the FDA registered. Insurance claims use a fixed 11-digit 5-4-2 format, so the short segment is padded with a leading zero and the dashes are dropped. The Identity section at the top of this page lists each form of this code.
Is this package still being marketed?
Yes, per the latest FDA NDC Directory data on this page: this package is listed as actively marketed, with no marketing end date reported by Nivagen Pharmaceuticals, Inc. Listing status can change — the directory data on this page refreshes weekly.
Does this product come in other package sizes?
Yes — the FDA directory lists 3 other package presentations of this same product, including 100 tablets (75834-0291-01), 500 tablets (75834-0291-05), 1000 tablets (75834-0291-00). Each has its own NDC and its own page — see the package list near the top of this page.
Who lists this product with the FDA?
Nivagen Pharmaceuticals, Inc is the labeler of record for this NDC — the company under whose FDA-assigned code the package is listed. The labeler may be the manufacturer itself or a distributor marketing the product under its own code.
This page identifies an FDA-listed package (the NDC) and reports public regulatory and pricing data about the listing. It is reference information, not a medical recommendation — talk to your pharmacist or prescriber about your own medication.
Where does this data come from?
Listing facts (marketing category, packager status, marketing dates) from the FDA openFDA NDC Directory; label availability from DailyMed; pricing coverage from CMS NADAC; equivalence scope from the FDA Orange Book.
← 75834-0290-00 · Nivagen 75834-0292-00 · Nivagen →
For educational and professional reference only — not medical advice. Pricing reflects published NADAC and CMS ASP (free public data) and may differ from your acquisition cost; always verify before billing or dispensing.